Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis

Objectives. Immune reconstitution therapies (IRT), which include antibody-based cell-depleting therapies targeting CD52+ (alemtuzumab) or CD20+ (rituximab, ocrelizumab) leukocytes, are approved for the treatment of multiple sclerosis. Thyroid autoimmunity is a common adverse effect of alemtuzumab tr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Duarte Diana Borges, Silva Ana Martins da, Freitas Claudia, Cardoso Helena
Formato:	article
Lenguaje:	EN
Publicado:	Sciendo 2021
Materias:	ocrelizumab graves´ disease immune reconstitution therapy multiple sclerosis Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/7f501c0e5c6b45d6a40e08bd41592731
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7f501c0e5c6b45d6a40e08bd41592731
record_format	dspace
spelling	oai:doaj.org-article:7f501c0e5c6b45d6a40e08bd415927312021-12-02T17:37:17ZGraves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis1336-032910.2478/enr-2021-0018https://doaj.org/article/7f501c0e5c6b45d6a40e08bd415927312021-07-01T00:00:00Zhttps://doi.org/10.2478/enr-2021-0018https://doaj.org/toc/1336-0329Objectives. Immune reconstitution therapies (IRT), which include antibody-based cell-depleting therapies targeting CD52+ (alemtuzumab) or CD20+ (rituximab, ocrelizumab) leukocytes, are approved for the treatment of multiple sclerosis. Thyroid autoimmunity is a common adverse effect of alemtuzumab treatment, Graves’ disease (GD) being the most prevalent manifestation. To date, thyroid autoimmunity events have not been reported with CD20-targeting monoclonal antibodies.Duarte Diana BorgesSilva Ana Martins daFreitas ClaudiaCardoso HelenaSciendoarticleocrelizumabgraves´ diseaseimmune reconstitution therapymultiple sclerosisDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENEndocrine Regulations, Vol 55, Iss 3, Pp 169-173 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ocrelizumab graves´ disease immune reconstitution therapy multiple sclerosis Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	ocrelizumab graves´ disease immune reconstitution therapy multiple sclerosis Diseases of the endocrine glands. Clinical endocrinology RC648-665 Duarte Diana Borges Silva Ana Martins da Freitas Claudia Cardoso Helena Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis
description	Objectives. Immune reconstitution therapies (IRT), which include antibody-based cell-depleting therapies targeting CD52+ (alemtuzumab) or CD20+ (rituximab, ocrelizumab) leukocytes, are approved for the treatment of multiple sclerosis. Thyroid autoimmunity is a common adverse effect of alemtuzumab treatment, Graves’ disease (GD) being the most prevalent manifestation. To date, thyroid autoimmunity events have not been reported with CD20-targeting monoclonal antibodies.
format	article
author	Duarte Diana Borges Silva Ana Martins da Freitas Claudia Cardoso Helena
author_facet	Duarte Diana Borges Silva Ana Martins da Freitas Claudia Cardoso Helena
author_sort	Duarte Diana Borges
title	Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis
title_short	Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis
title_full	Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis
title_fullStr	Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis
title_full_unstemmed	Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis
title_sort	graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis
publisher	Sciendo
publishDate	2021
url	https://doaj.org/article/7f501c0e5c6b45d6a40e08bd41592731
work_keys_str_mv	AT duartedianaborges gravesdiseasewithspontaneousresolutionfollowingocrelizumabinprimaryprogressivemultiplesclerosis AT silvaanamartinsda gravesdiseasewithspontaneousresolutionfollowingocrelizumabinprimaryprogressivemultiplesclerosis AT freitasclaudia gravesdiseasewithspontaneousresolutionfollowingocrelizumabinprimaryprogressivemultiplesclerosis AT cardosohelena gravesdiseasewithspontaneousresolutionfollowingocrelizumabinprimaryprogressivemultiplesclerosis
_version_	1718379892040531968

Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis

Ejemplares similares